On 8 September 2026, Sandoz announced that it is aiming to establish a portfolio of more than 100 biosimilars by 2040 as part of its Bio100 plan to maximise value in the “golden decade” for biosimilars. According to Sandoz, over the next 10 years, medicines worth more than USD 650 billion dollars are set to lose exclusivity, representing an unprecedented “golden decade” for patient access to more affordable medicines.
Sandoz currently markets 13 biosimilars and, in addition to substantially increasing that number over the next 14 years, the company plans to more than double its net sales from 2025 to 2035 and achieve a core EBITDA margin above 30%.
As part of Bio100, Sandoz has also announced its plans to build a new biosimilar drug manufacturing facility in Ljubljana, Slovenia. The project will involve a US $300 million investment in disposable fed-batch technology to expand Sandoz’s in-house manufacturing capacity and strengthen end-to-end biosimilar development and manufacturing in Europe.
This manufacturing facility is additional to previously announced investments in Slovenia. The facility is expected to become operational in 2029 and will be located next to Sandoz’s biosimilar development centre, which opened in June 2026.